What Century Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 3 |
| Sells | 5 | 20 |
| Total trades | 8 | 41 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 2,000,120 |
| Disposed | 50,793 | 323,535 |
| Net activity | −50,793 | +1,676,585 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Russotti Gregory | See Remarks | Sep 14 | Open-market sale · S | −2,587 | $1.93 | −$4.99K | 509,198 |
| Carr Douglas | SVP Finance & Operations | Sep 14 | Open-market sale · S | −1,658 | $1.93 | −$3.2K | 502,907 |
| Pfeiffenberger Brent | President and CEO | Sep 11 | Withheld — tax / exercise cost · F | −13,850 | $1.94 | −$26.9K | 3,633,839 |
| Carr Douglas | SVP Finance & Operations | Sep 08 | Open-market sale · S | −254 | $2.05 | −$521 | 504,565 |
| Russotti Gregory | See Remarks | Sep 08 | Open-market sale · S | −534 | $2.05 | −$1.09K | 511,785 |
| Pfeiffenberger Brent | President and CEO | Sep 04 | Withheld — tax / exercise cost · F | −463 | $2.11 | −$977 | 3,633,839 |
| Pfeiffenberger Brent | President and CEO | Aug 14 | Withheld — tax / exercise cost · F | −31,172 | $1.92 | −$59.9K | 3,634,302 |
| Carr Douglas | SVP Finance & Operations | Aug 03 | Open-market sale · S | −275 | $1.98 | −$544 | 504,819 |
| Carr Douglas | SVP Finance & Operations | Jun 12 | Open-market sale · S | −1,654 | $2.23 | −$3.69K | 505,094 |
| Russotti Gregory | See Remarks | Jun 12 | Open-market sale · S | −2,584 | $2.23 | −$5.77K | 512,319 |
| Cowan Chad | Chief Scientific Officer | Jun 11 | Withheld — tax / exercise cost · F | −358 | $2.24 | −$802 | 1,175,322 |
| Pfeiffenberger Brent | President and CEO | Jun 11 | Withheld — tax / exercise cost · F | −13,849 | $2.24 | −$31K | 3,665,474 |
| Carr Douglas | SVP Finance & Operations | Jun 08 | Open-market sale · S | −249 | $2.11 | −$526 | 506,748 |
| Russotti Gregory | See Remarks | Jun 08 | Open-market sale · S | −524 | $2.11 | −$1.11K | 514,903 |
| Pfeiffenberger Brent | President and CEO | Jun 05 | Withheld — tax / exercise cost · F | −463 | $2.13 | −$986 | 3,679,323 |
| Pfeiffenberger Brent | President and CEO | May 15 | Withheld — tax / exercise cost · F | −31,172 | $2.34 | −$72.9K | 3,679,786 |
| Carr Douglas | SVP Finance & Operations | May 04 | Open-market sale · S | −264 | $2.34 | −$618 | 506,997 |
| Cowan Chad | Chief Scientific Officer | Apr 01 | Withheld — tax / exercise cost · F | −1,365 | $2.19 | −$2.99K | 1,175,680 |
| Carr Douglas | SVP Finance & Operations | Mar 12 | Open-market sale · S | −7,043 | $2.55 | −$18K | 507,261 |
| Russotti Gregory | See Remarks | Mar 12 | Open-market sale · S | −10,076 | $2.55 | −$25.7K | 515,427 |
Loading...